Skip to main content

Table 4 Decision criteria per treatment strategy at current period

From: A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies

Decision criteria (Score 1–10)

Treatment Strategy

P

A

B

C

Median

IQR

Median

IQR

Median

IQR

Adjustment to patient’s peculiarities, principles / values & personal characteristics

10

(9–10)

9

(8–10)

8

(7–10)

< 0.01

Simplicity and convenience of treatment regimen

10

(9–10)

9

(8–10)

8

(7–9)

< 0.01

Compliance with International and Greek Guidelines for the management of DM-2

10

(9–10)

10

(8–10)

9

(8–10)

< 0.01

Choice due to corresponding physician’s clinical experience and / or familiarity

10

(9–10)

9

(8–10)

9

(8–10)

< 0.01

Compliance with the specific administration indications of the formulations

10

(9–10)

9

(8–10)

9

(8–10)

< 0.02

Compliance with Prescribing Guidelines from Regulatory Agencies or Insurance Funds

10

(8–10)

9

(8–10)

9

(8–10)

< 0.01

Greater Efficacy of the specific treatment

10

(9–10)

9

(8–10)

9

(8–10)

< 0.02

Greater Safety of the specific treatment

10

(9–10)

9

(8–10)

9

(8–10)

0.01

Better efficacy / safety combination with the specific treatment

10

(9–10)

9

(8–10)

9

(8–10)

< 0.01

Pursuing the lowest possible cost for the patient

10

(8–10)

8

(7–10)

8

(6–9)

< 0.01

Pursuing the lowest possible burden for Government Funds

10

(8–10)

8

(6–10)

8

(6–9)

< 0.01

Better financial cost and clinical benefit (efficacy) ratio

10

(8–10)

9

(8–10)

8

(7–9)

< 0.01

Minimization of adverse reactions from treatment

10

(9–10)

9

(8–10)

9

(8–10)

< 0.01